Q3 2025 13F Holders as of 9/30/2025
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
3.15M
-
Number of holders
-
20
-
Total 13F shares, excl. options
-
374K
-
Shares change
-
+176K
-
Total reported value, excl. options
-
$222K
-
Value change
-
+$22.2K
-
Number of buys
-
7
-
Number of sells
-
-7
-
Price
-
$0.59
Significant Holders of GT Biopharma, Inc. - Common Stock (GTBP) as of Q3 2025
23 filings reported holding GTBP - GT Biopharma, Inc. - Common Stock as of Q3 2025.
GT Biopharma, Inc. - Common Stock (GTBP) has 20 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 374K shares
of 3.15M outstanding shares and own 11.89% of the company stock.
Largest 10 shareholders include DRW Securities, LLC (142K shares), BANK OF MONTREAL /CAN/ (92.5K shares), CITADEL ADVISORS LLC (39.6K shares), GEODE CAPITAL MANAGEMENT, LLC (24K shares), TWO SIGMA SECURITIES, LLC (17.1K shares), MORGAN STANLEY (14K shares), VANGUARD GROUP INC (10.5K shares), WELLS FARGO & COMPANY/MN (10K shares), BlackRock, Inc. (9.74K shares), and OSAIC HOLDINGS, INC. (5.07K shares).
This table shows the top 20 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.